Global food and beverage companies from PepsiCo to Coca-Cola are focusing on shorter ingredient lists and smaller pack sizes as more people take appetite-suppressing GLP-1 drugs for weight loss.
Companies that previously took a wait-and-see attitude now see these drugs as being here to stay.
Diet changes linked to GLP-1 drug use could mean up to $12 billion in snack sales lost over the next decade, according to EY-Parthenon estimates.
Today's Econ World podcast is also pondering GLP-1s as host Carmel Crimmins talks to Global Health Editor Michele Gershberg and US Business Editor David Gaffen about the impact of falling obesity rates on consumer spending, productivity and government finances. Listen here.
Reuters One Essential Read is sent three days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.
Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.
Global food and beverage companies from PepsiCo to Coca-Cola are focusing on shorter ingredient lists and smaller pack sizes in 2026 as more people take appetite-suppressing GLP-1 drugs for weight loss.
Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.
Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.
